Elizabeth Cheesman
Brisbane, QLD, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
β1- and β2-adrenergic receptor mediated spontaneous contractions and ryanodine receptor channel opening in human failing heart.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 10, 2026
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.
Journal: Cell
Published: August 29, 2025
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.
Journal: Cell
Published: June 28, 2024
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis.
Journal: Molecular metabolism
Published: January 12, 2024
Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
Journal: Pharmacology research & perspectives
Published: February 08, 2021
Correction to "Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure".
Journal: ACS pharmacology & translational science
Published: September 22, 2020
A Rare Case of Severe Nontropical Isolated Right Ventricular Endomyocardial Fibrosis.
Journal: JACC. Case reports
Published: March 13, 2020
Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure.
Journal: ACS pharmacology & translational science
Published: January 09, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026